Abstract:Objective Adult complicated intra-abdominal infection (cIAI) are multiple bacterial mixed infections caused by various reasons.To study the clinical efficacy and safety of moxifloxacin in the treatment of cIAI in adults to provide reference in the clinical practice. Methods The cIAI patients met inclusion criteria were prospectively selected from January 2017 to January 2019 and randomly divided into moxifloxacin group and control group.In moxifloxacin group,moxifloxacin hydrochloride injection 20 ml was added into 5% glucose solution or of normal saline 250 ml for intravenous drip once a day.In control group,2.0 g ceftazidime was added into 100 ml normal saline for intravenous drip once every 8 hours,and 0.5% metronidazole sodium chloride 100 ml was given by intravenous drip once every 12 hours.Both groups were administered continuously for 7-14 days.At 1-7 days after the end of treatment,the therapeutic efficacy and adverse reactions were compared between two groups. Results A total of 110 patients were enrolled,53 cases in moxifloxacin group,and 40 cases were positive for bacterial culture;57 cases in control group and 42 cases were positive for bacterial culture. The demographic and clinical characteristics were similar in two groups(all P>0.05).There were no significant differences in clinical cure rate ［96.2% (51/53) vs 96.5%（55/57）］and the bacterial clearance rate ［95.0% (38/40) vs 95.2% (40/42)］ between moxifloxacin group and control group and in the incidence of adverse reactions(mainly nausea and hypokalemia) between two groups（all P>0.05）.No serious adverse events occurred in two groups. ConclusionIn the treatment of cIAI in adults,moxifloxacin monotherapy is effective,safe and convenient,and with adverse reactions similar to those of ceftazidime and metronidazole.